• 1
    Cyclosporin A as sole immunosuppressive agents in recipients of kidney allografts from cadaver donors. Preliminary results of a European Multicenter trial. Lancet 1982; 2: 5760.
  • 2
    A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309: 809815.
  • 3
    Merion RN, White DJG, Thiru S, Evans DB, Calne RY. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med 1984; 310: 148154.
  • 4
    Sollinger HW.Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225232.
  • 5
    European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 13211325.
  • 6
    The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1995; 61: 10291037.
  • 7
    Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS.A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977983.
  • 8
    Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194202.
  • 9
    McDonald AS. A worldwide, Phase III, randomized, controlled safety and efficacy study of a sirolimus/cyclosporine regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271280.
  • 10
    Vincenti F, Kirkman R, Light S et al. Interluekin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Eng J Med 1998; 338: 17001701.
  • 11
    Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999; 67: 276284.
  • 12
    Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantations in recipient in the United States, 1988 to 1996. N Engl J Med 1999; 342: 605612.
  • 13
    Halloran P, Mathew S, Tamlonovith S et al. Mycophenolate Mofetil in renal allograft recipients. A pooled analysis of three randomized, double blind, clinical studies in prevention of acute rejection. Transplantation 1997; 63: 3947.
  • 14
    Hariharan S, Jindal R. Chronic rejection in kidney transplants: an in depth review. Nephron 1999; 83: 1324.
  • 15
    Mathew TH. A blinded, long-term, randomized, multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Results at 3 years. Transplantation 1998; 65: 14501454.
  • 16
    US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kid Dis 1999; 34: 296303.
  • 17
    Mycophenolate mofetil in renal transplantation: 3 year results from the placebo-controlled trial. Transplantation 1999; 68: 391396.
  • 18
    Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at 5 years. Transplantation 2002; 73: 775782.
  • 19
    Govani MV, Kwon O, Batiuk TD, Milgrom ML, Filo RS. Creatinine reduction ratio and 24 hour creatinine excretion on post transplant day two. Simple and objective tools to define graft function. J Am Soc Nephrol 2002; 13: 16451649.
  • 20
    CeckaMJ, TerasakiPI, eds. The UNOS Scientific Renal Transplant Registry, in Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1998: 116.
  • 21
    Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311318.
  • 22
    Giral M, Taddei C, Nguyen JM et al. Single center analysis of 468 first cadaveric kidney allograft with uniform ATG-CsA sequential therapy. In: CeckaMJ, TerasakiPI, eds. Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1996: 257264.
  • 23
    Tesi RJ, Bailly JE, Schnitzler MA, Irish WD. Development of a surrogate marker of long-term kidney allograft outcome based on serum creatinine and calculated creatinine clearance at 6 months post-transplant. Am J Transplantation 2002; 2 (A46): 149.
  • 24
    Kasiske BL, Andany MA, Hernandez D et al. Comparing methods for monitoring serum creatinine to predict late renal allograft survival. Am J Kid Dis 2001; 38: 10651073.
  • 25
    Le Bricon T, Thervet E, Benlakehal M, Bousquet B, Legendre C, Erlich D. Changes in plasma cystatin C after renal transplantation and acute rejection in adults. Clin Chem 2000; 46: 12061207.
  • 26
    Paskalev E, Lambreva L, Simeonov P et al. Serum cystatin C in renal transplant patients. Clin Chim Acta 2001; 310: 5356.
  • 27
    Rush D, Nickerson P, Gough J et al. Beneficial effect of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9: 21292134.
  • 28
    Gloor JM, Cohen AJ, Lager DJ et al. Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 2002; 73: 19651968.
  • 29
    Isoniemi H, Taskinen E, Hayry P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 1994; 58: 11951198.
  • 30
    Nankivel BJ, Fenton-Lee CA, Kuypers DR et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515523.
  • 31
    Crocker BP, Clapp WL, Abu Shamat AR, Kone BC, Peterson JC. Macrophage and chronic renal allograft nephropathy. Kidney Int 1996; 57: S42S49.
  • 32
    Oikawa T, Morozumi K, Koyama K et al. Electron microscopic peritubular capillary lesions: a new criterion for chronic rejection. Clin Transplant 1999; 13 (Suppl. 1): S24S32.
  • 33
    Nicholson ML, Bailey E, Williams S, Harris KP, Furness PN. Computerized histomorphometric assessment of protocol renal transplant biopsy specimen for surrogate markers of chronic rejection. Transplantation 1999; 68: 236241.
  • 34
    Seron D, Moreso F, Ramon JM et al. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 2000; 69: 18491855.
  • 35
    Hariharan S, McBride M, Bennett L, Cohen EP. Risk factors for renal allograft survival from older cadaver donors. Transplantation 1997; 64: 17481754.
  • 36
    Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve year's experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000; 343: 10781084.
  • 37
    Supon P, Constantino D, Hao P et al. Prevalence of donor-specific anti-HLA antibodies during episodes of renal allograft rejection. Transplantation 2001; 71: 577580.
  • 38
    Khanna AK. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation 2000; 70: 690694.
  • 39
    Li B, Hartono C, Ding B et al. Noninvasive diagnosis of renal allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344: 947954.
  • 40
    Wolfe RA, Ashby VB, Milford El et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of first cadaveric transplants. N Engl J Med 1999; 341: 17251730.
  • 41
    Hariharan S. Long-term kidney transplant survival. Am J Kid Dis 2001; 38 (Suppl. 6): S44S50.